NCT07036328Recruiting
Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease
Transcranial Magnetic Stimulation (TMS) to Slow Down Cognitive Decline in Alzheimer's Disease (AD): TMSLA - a Monocentric Randomized Controlled Trial.
Source: ClinicalTrials.gov · Last updated 12 May 2026
Brief summary (registry, in English)
New amyloid-targeting drugs for Alzheimer's disease (AD) offer minimal or unclear efficacy and often cause adverse events, highlighting the need for new therapies. In recent years, repetitive transcranial magnetic stimulation (rTMS) has shown increasing success. A recent randomized, double-blind, sham-controlled, phase 2 demonstrated promising results from a 24-week rTMS treatment protocol targeting the precuneus. This brain region is considered a main hub of the human brain connectome and a prominent area of AD pathology. The results showed stable cognitive performance and increased brain activity in the treatment group, whereas the sham group worsened. A replication study is planned to further investigate the working mechanism of precuneus-rTMS in AD and to improve understanding of its therapeutic potential.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 55 (estimated)
- First submitted
- 24 Apr 2025
- Start date
- Apr 2025
- Primary completion date
- Jan 2028
- Lead sponsor
- Willem de Haan
- Diseases
- Alzheimer disease
- NCT number
- NCT07036328
What you commit to
- Study type: Interventional
- Planned participants: 55
- From Apr 2025 to the primary completion date, Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Presence of metal in the head or cranial/thoracic implants, including cochlear implants.
- Cholinesterase inhibitors with unstable dosage in the last 2 months.
- Previous rTMS treatment (for blinding reasons).
Other illness
- Medical history of neurodegenerative diseases other than AD, stroke, or epilepsy.
- Severe psychiatric dysregulation, hampering successful study participation and leading to possible cognitive impairment. Eligibility for participation will be based on clinical evaluation by an expert neurologist and/or psychiatrist.
Other
- Extensive cerebrovascular damage on MRI classified as Fazekas level 2 or 3. Patients with abnormalities classified as Fazekas level 3 are excluded. For Fazekas level 2, patient's eligibility for participation will be evaluated by an expert neurologist.
- Extreme claustrophobia or metallic objects in or on the body, preventing MRI and MEG examination.
Who the study is looking for
- Biomarker-supported Alzheimer's disease (abnormal CSF p-tau/Aβ42 ratio of \> 0.023 or amyloid PET positive).
- Between 50 and 85 years old.
- Clinical Dementia Rating (CDR) score of 0.5 or 1.
- Mini-Mental State Examination (MMSE) score between 18 and 27.
- Presence of a caregiver.
Age in the registry: 50 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam UMC Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.